EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers

Jianan Jin iD, Haibo Mou, Yibin Zhou, Shiqi Zhang

Cancer Control · 2024-01 · 31

DOI: 10.1177/10732748241305237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Control, online erschienen am 05.12.2024. Verfasst von Jianan Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Zhejiang Chinese Medical University, Hangzhou, P.R. China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Nomograms, Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma.

Methods

This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves.

Results

Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaNomogramsBile Duct NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedBiomarkers, TumorAgedROC CurveImmunotherapyNeutrophilsPrognosisLymphocytes

Stichwörter der Autor:innen

PD-1/PD-L1cholangiocarcinomanomogramsurvival

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Graduate School, Zhejiang Chinese Medical University, Hangzhou, P.R. China.
  • Department of Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, P.R. China.

ORCID-Profile: Jianan Jin

Zitieren

APA

Jin, J., Mou, H., Zhou, Y., & Zhang, S. (2024). Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control, 31. https://doi.org/10.1177/10732748241305237

Vancouver

Jin J, Mou H, Zhou Y, Zhang S. Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control. 2024;31. doi:10.1177/10732748241305237

BibTeX
@article{Jin2024,
  author = {Jin, Jianan and Mou, Haibo and Zhou, Yibin and Zhang, Shiqi},
  title = {Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers},
  journal = {Cancer Control},
  year = {2024},
  volume = {31},
  doi = {10.1177/10732748241305237}
}
Kostenlos starten →